Skip to main content

Table 1 Baseline characteristics of patients treated with amikacin

From: Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada

Baseline characteristics N = 107 (%)
Sex, Female 70 (65.4)
Age (Years), Mean (SD) 58.3 (14.9)
Race
 Caucasian 72 (67.3)
 South Asian 4 (3.7)
 East Asian 28 (26.2)
 African 3 (2.8)
Comorbidities
 COPD/Emphysema 19 (17.7)
 Previous TB 13 (12.1)
 Cystic fibrosis 6 (5.6)
 Asthma 5 (4.7)
 Autoimmune disorders 5 (4.7)
 Alpha 1 antitrypsin deficiency 2 (1.9)
 Sarcoidosis 2 (1.9)
 ABPA 2 (1.9)
 Allogenic stem cell transplant 2 (1.9)
 HIV infection 1 (0.9)
Species
 MACa 69 (64.5)
M. abscessus 21 (19.6)
M. xenopi 11 (10.3)
 MAC and M. xenopi 4 (3.7)
M. shimodei 1 (0.9)
M. fortuitum 1 (0.9)
AFB smear positive ever 100 (93.5)
Aspergillus isolation 39 (36.4)
CT pattern
 Nodular bronchiectatic 55 (51.4)
 Fibrocavitary 40 (37.4)
 Random nodules 2 (1.9)
 Consolidation 0 (0)
 Unclassifiable 10 (9.3)
Cavity 66 (61.7)
Indication for treatment
 First line 39 (36.4)
 Second line 68 (63.6)
  1. SD Standard deviation, COPD Chronic Obstructive Pulmonary Disease, TB Tuberculosis, SLE Systemic Lupus Erythematous, ABPA Allergic Bronchopulmonary Aspergillosis, HIV Human Immunodeficiency Virus, MAC Mycobacterium avium complex, AFB Acid Fast Bacilli, CT Computed Tomography
  2. aFive patients had Clarithromycin resistant MAC; MAC isolates were not identified to the species level prior to 2010, and so are reported as MAC herein